Income Statement (MESOBLAST)

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-… [+1556 chars]...

Shares of Mesoblast Limited (NASDAQ:MESO – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $11.69, but opened at $11.00. Mesoblast shares last traded at $… [+2638 chars]...

Mesoblast Limited (NASDAQ:MESO – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Mesoblast in a report issued on Mo… [+2567 chars]...

Rhumbline Advisers decreased its position in shares of Mesoblast Limited (NASDAQ:MESO – Free Report) by 37.6% during the first quarter, HoldingsChannel reports. The fund owned 5,833 shares of the com… [+3046 chars]...

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum … [+8032 chars]...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United State… [+7234 chars]...